Halozyme Therapeutics, Inc.

Healthcare · Biotechnology

Overall research band Strong

Quality Exceptional

Valuation Exceptional

Balance sheet Weak

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Halozyme Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, with international operations. The company specializes in the ENHANZE drug delivery platform, which uses a patented recombinant human hyaluronidase enzyme (rHuPH20) to improve subcutaneous administration of injectable medicines, including biologics, monoclonal antibodies, and other therapeutic molecules. Its main product, Hylenex recombinant, facilitates subcutaneous fluid delivery and enhances the absorption of injected drugs. Halozyme's platform is used in therapeutics such as Perjeta, RITUXAN HYCELA, MabThera SC, RITUXAN SC, and HYQVIA, targeting conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and immunodeficiency disorders. The company has a pipeline of investigational drugs for cancer, autoimmune, and other diseases, and generates revenue through collaborations and partnerships with major pharmaceutical companies and research institutions.

The current research profile is Market-Leading Quality, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC29.1%Model input; read with the evidence status and period context.

Operating margin58.4%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years33.2%Model input; read with the evidence status and period context.

FCF margin46.2%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.